Search

Your search keyword '"Stockmann, H B"' showing total 148 results
Start Over Author "Stockmann, H B"
148 results on '"Stockmann, H B"'

6. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial

Author

Hop, W C, Opmeer, B C, Reitsma, J B, Scholte, R A, Waltmann, E W H, Legemate, D A, Bartelsman, J F, Meijer, D W, de Brouwer, M, van Dalen, J, Durbridge, M, Geerdink, M, Ilbrink, G J, Mehmedovic, S, Middelhoek, P, Di Saverio, Salomone, Boom, M J, Consten, E C J, van der Bilt, J D W, van Olden, G D J, Stam, M A W, Verweij, M S, Busch, O R C, Buskens, C J, El-Massoudi, Y, Kluit, A B, van Rossem, C C, Schijven, M P, Tanis, P J, Unlu, C, Gerhards, M F, Karsten, T M, de Nes, L C, Rijna, H, van Wagensveld, B A, Koffeman, G I, Steller, E P, Tuynman, J B, Bruin, S C, van der Peet, D L, Blanken-Peeters, C F J M, Cense, H A, Jutte, E, Crolla, R M P H, van der Schelling, G P, van Zeeland, M, de Graaf, E J R, Groenendijk, R P R, Vermaas, M, Schouten, O, de Vries, M R, Prins, H A, Lips, D J, Bosker, R J I, van der Hoeven, J A B, Diks, J, Plaisier, P W, Kruyt, P M, Sietses, C, Stommel, M W J, Nienhuijs, S W, de Hingh, I H J T, Luyer, M D P, van Montfort, G, Ponten, E H, Smulders, J F, van Duyn, E B, Klaase, J M, Swank, D J, Ottow, R T, Stockmann, H B A C, Vermeulen, J, Vuylsteke, R J C L M, Belgers, H J, Fransen, S, von Meijenfeldt, E M, Sosef, M N, van Geloven, A A W, Hendriks, E R, ter Horst, B, Leeuwenburgh, M M N, van Ruler, O, Vogten, J M, Vriens, E J C, Westerterp, M, Eijsbouts, Q A J, Bentohami, A, Bijlsma, T S, de Korte, N, Nio, D, Govaert, M J P M, Joosten, J J A, Tollenaar, R A E M, Stassen, L P S, Wiezer, M J, Hazebroek, E J, Smits, A B, van Westreenen, H L, Lange, J F, Brandt, A, Nijboer, W N, Toorenvliet, B R, Weidema, W F, Coene, P P L O, Mannaerts, G H H, den Hartog, D, de Vos, R J, Zengerink, J F, Hoofwijk, A G M, Hulsewé, K W E, Melenhorst, J, Stoot, J H M B, Steup, W H, Huijstee, P J, Merkus, J W S, Wever, J J, Maring, J K, Heisterkamp, J, van Grevenstein, W M U, Vriens, M R, Besselink, M G H, Borel Rinkes, I H M, Witkamp, A J, Slooter, G D, Konsten, J L M, Engel, A F, Pierik, E G J M, Frakking, T G, van Geldere, D, Patijn, G A, D'Hoore, A J L, de Buck van Overstraeten, A, Miserez, M, Terrasson, I, Wolthuis, A, De Blasiis, M G, Vennix, Sandra, Musters, Gijsbert D, Mulder, Irene M, Swank, Hilko A, Consten, Esther C, Belgers, Eric H, van Geloven, Anna A, Gerhards, Michael F, Govaert, Marc J, van Grevenstein, Wilhelmina M, Hoofwijk, Anton G, Kruyt, Philip M, Nienhuijs, Simon W, Boermeester, Marja A, Vermeulen, Jefrey, van Dieren, Susan, Lange, Johan F, and Bemelman, Willem A

Published
2015
Full Text
View/download PDF

10. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT‐proven uncomplicated acute diverticulitis

Author

Daniels, L., Ünlü, Ç., de Korte, N., van Dieren, S., Stockmann, H. B., Vrouenraets, B. C., Consten, E. C., van der Hoeven, J. A., Eijsbouts, Q. A., Faneyte, I. F., Bemelman, W. A., Dijkgraaf, M. G., Boermeester, M. A., Glaap, C. E. M., Croonen, A., Cuesta, M. A., Kuijvenhoven, J., Buijsman, R., Den Uil, S., De Reuver, P. R., Tuynman, J. B., Van de Wall, B. J. M., Stam, M. A. W., Roumen, R. M. H., Truin, W., Wijn, R., Gerhards, M. F., Kuhlmann, K. F. D., Van der Zaag, E. S., Biemond, J. E., Klicks, R. J., Dhar, N., Cense, H. A., De Groot, G. H., Pikoulin, Y., Van Ramshorst, G. H., Hoornweg, L. L., Koet, L., Van Geloven, A. A. W., Emous, M., Claassen, A. T. P. M., Mollink, S., Sonneveld, D. J. A., Bouvé, L., Diepenhorst, G. M. P., Vles, W. J., Toorenvliet, B. R., Lange, J. F., Mannaerts, G. H. H., Grotenhuis, B. A., tot Nederveen Cappel, R. J. De Vos, Deerenberg, E. B., Depla, A. C. T. M., Bruin, S., Vos, X., Scheepers, J. J. G., Boom, M. J., Boerma, D., Van Esser, S., Pruim, J., and Reitsma, J. B.

Published
2017
Full Text
View/download PDF

12. Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial)

Author

Abis, G. S. A., Stockmann, H. B. A. C., Bonjer, H. J., van Veenendaal, N., van Doorn-Schepens, M. L. M., Budding, A. E., Wilschut, J. A., van Egmond, M., Oosterling, S. J., de Lange, E. S. M., Tuynman, J. B., e. Vandenbroucke-Grauls, C. M. J., C. Stockmann, H. B. A., van der Bij, G. J., de Korte, N., Acherman, Y. I. Z., den Boer, F. C., Sonneveld, D. J. A., Poort, L., e Vandenbroucke-Grauls, C. M. J., C Stockmann, H. B. A., VU University medical center, CCA - Cancer Treatment and quality of life, APH - Quality of Care, APH - Global Health, Surgery, Medical Microbiology and Infection Prevention, AGEM - Digestive immunity, AII - Infectious diseases, Epidemiology and Data Science, Molecular cell biology and Immunology, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer biology and immunology, and ACS - Microcirculation

Subjects
Male, musculoskeletal diseases, medicine.medical_specialty, Colectomies, Colorectal cancer, Cefazolin, 030230 surgery, Anastomosis, Risk Assessment, law.invention, Hospitals, University, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Reference Values, Preoperative Care, medicine, Humans, Surgical Wound Infection, Antibiotic prophylaxis, Colectomy, Decontamination, Aged, Netherlands, Academic Medical Centers, Analysis of Variance, business.industry, Anastomosis, Surgical, Perioperative, Antibiotic Prophylaxis, Middle Aged, Interim analysis, medicine.disease, Surgery, Treatment Outcome, Elective Surgical Procedures, Multivariate Analysis, Tobramycin, 030211 gastroenterology & hepatology, Female, business, Colorectal Neoplasms, medicine.drug, Follow-Up Studies
Abstract

Background Infectious complications and anastomotic leakage affect approximately 30 per cent of patients after colorectal cancer surgery. The aim of this multicentre randomized trial was to investigate whether selective decontamination of the digestive tract (SDD) reduces these complications of elective colorectal cancer surgery. Methods The effectiveness of SDD was evaluated in a multicentre, open-label RCT in six centres in the Netherlands. Patients with colorectal cancer scheduled for elective curative surgery with a primary anastomosis were eligible. Oral colistin, tobramycin and amphotericin B were administered to patients in the SDD group to decontaminate the digestive tract. Both treatment and control group received intravenous cefazolin and metronidazole for perioperative prophylaxis. Mechanical bowel preparation was given for left-sided colectomies, sigmoid and anterior resections. Anastomotic leakage was the primary outcome; infectious complications and mortality were secondary outcomes. Results The outcomes for 228 patients randomized to the SDD group and 227 randomized to the control group were analysed. The trial was stopped after interim analysis demonstrated that superiority was no longer attainable. Effective SDD was confirmed by interspace DNA profiling analysis of rectal swabs. Anastomotic leakage was observed in 14 patients (6·1 per cent) in the SDD group and in 22 patients (9·7 per cent) in the control group (odds ratio (OR) 0·61, 95 per cent c.i. 0·30 to 1·22). Fewer patients in the SDD group had one or more infectious complications than patients in the control group (14·9 versus 26·9 per cent respectively; OR 0·48, 0·30 to 0·76). Multivariable analysis indicated that SDD reduced the rate of infectious complications (OR 0·47, 0·29 to 0·76). Conclusion SDD reduces infectious complications after colorectal cancer resection but did not significantly reduce anastomotic leakage in this trial. Registration number: NCT01740947 (https://www.clinicaltrials.gov).

Published
2019

14. The learning curve of transanal total mesorectal excision for rectal cancer is associated with local recurrence: results from a multicentre external audit:results from a multicentre external audit

Author

van Oostendorp, Stefan E., Belgers, H. J., Hol, Jeroen C., Doornebosch, Pascal G., Belt, Eric J. Th., Oosterling, Steven J., Kusters, Miranda, Bonjer, H. J., Sietses, Colin, Tuynman, Jurriaan B., Boerma, E. J., Creemers, D., Graaf, E. J. De, van der Hoeven, J. A. B., Sosef, M. N., Stockmann, H. B. A. C., van der Stok, E. P., Vuylsteke, R. C. L. M., Surgery, CCA - Cancer Treatment and quality of life, APH - Global Health, APH - Quality of Care, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

Aim: Transanal total mesorectal excision (TaTME) has been suggested as a potential solution for the resection of challenging mid and low rectal cancer. This relatively complex procedure has been implemented in many centres over the last years, despite the absence of long-term safety data. Recently, concern has arisen because of an increase in local recurrence in the implementation phase. The aim of this study was to assess the correlation between accumulated experience and local recurrences. Method: An independent clinical researcher performed an external audit of consecutive series of all TaTME procedures in six centres in the Netherlands. Kaplan–Meier estimated local recurrence rates were calculated and multivariate Cox proportional hazards regression analysis performed to assess risk factors for local recurrence. Primary outcome was the local recurrence rate in the initial implementation (cases 1–10), continued adoption (cases 11-40) and prolonged experience (case 41 onward). Results: Six hundred and twenty-four consecutive patients underwent TaTME for rectal cancer with a median follow-up of 27 months (range 1–82 months). The estimated 2- and 3-year local recurrence rates were 4.6% and 6.6%, respectively. Cox proportional hazards regression revealed procedural experience to be an independent factor in multivariate analysis next to advanced stage (ycMRF+, pT3-4, pN+) and pelvic sepsis. Corrected analysis projected the 3-year local recurrence rates to be 9.7%, 3.3% and 3.5% for the implementation, continued adoption and prolonged experience cohorts, respectively. Conclusion: This multicentre study shows a high local recurrence rate (12.5%) after implementation of TaTME which lowers to an acceptable rate (3.4%) when experience increases. Therefore, intensified proctoring and further precautions must be implemented to reduce the unacceptably high risk of local recurrence at units starting this technique.

Published
2021

19. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer

Author

Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, CCA - Cancer Treatment and Quality of Life, AGEM - Re-generation and cancer of the digestive system, Surgery, Lifelong Learning, Education & Assessment Research Network (LEARN), Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Lung Neoplasms, Esophageal Neoplasms, SURGERY, medicine.medical_treatment, Kaplan-Meier Estimate, RADICAL ESOPHAGECTOMY, Gastroenterology, Metastasis, COLORECTAL-CANCER, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], hepatic surgery, 0302 clinical medicine, Pulmonary metastasis, Medicine, Registries, Prospective cohort study, Neoadjuvant therapy, Netherlands, Liver Neoplasms, SURGICAL RESECTION, esophageal and gastric cancer, General Medicine, CHEMOTHERAPY, Middle Aged, Combined Modality Therapy, Survival Rate, Treatment Outcome, Esophagectomy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Original Article, Female, Metastasectomy, pulmonary surgery, Erratum, medicine.medical_specialty, CARCINOMA, RECURRENCE PATTERN, Resection, LIVER METASTASES, CHEMORADIOTHERAPY, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Gastrectomy, Stomach Neoplasms, Internal medicine, Carcinoma, metastasis, Humans, Aged, esophageal and gastric surgery, business.industry, Neuroendocrine neoplasm, Cancer, LONG-TERM SURVIVAL, medicine.disease, Surgery, business, Author name, Chemoradiotherapy
Abstract

SUMMARY The standard of care for gastroesophageal cancer patients with hepatic or pulmonary metastases is best supportive care or palliative chemotherapy. Occasionally, patients can be selected for curative treatment instead. This study aimed to evaluate patients who underwent a resection of hepatic or pulmonary metastasis with curative intent. The Dutch national registry for histo- and cytopathology was used to identify these patients. Data were retrieved from the individual patient files. Kaplan–Meier survival analysis was performed. Between 1991 and 2016, 32,057 patients received a gastrectomy or esophagectomy for gastroesophageal cancer in the Netherlands. Of these patients, 34 selected patients received a resection of hepatic metastasis (n = 19) or pulmonary metastasis (n = 15) in 21 different hospitals. Only 4 patients received neoadjuvant therapy before metastasectomy. The majority of patients had solitary, metachronous metastases. After metastasectomy, grade 3 (Clavien–Dindo) complications occurred in 7 patients and mortality in 1 patient. After resection of hepatic metastases, the median potential follow-up time was 54 months. Median overall survival (OS) was 28 months and the 1-, 3-, and 5- year OS was 84%, 41%, and 31%, respectively. After pulmonary metastases resection, the median potential follow-up time was 80 months. The median OS was not reached and the 1-, 3-, and 5- year OS was 67%, 53%, and 53%, respectively. In selected patients with gastroesophageal cancer with hepatic or pulmonary metastases, metastasectomy was performed with limited morbidity and mortality and offered a 5-year OS of 31–53%. Further prospective studies are required.

Published
2020

24. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer : a nationwide study

Author

Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, and van Workum, F

Published
2019

25. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study

Author

MS CGO, Cancer, Heelkunde Opleiding, Pathologie Pathologen staf, Divisie Beeld & Oncologie, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, MS CGO, Cancer, Heelkunde Opleiding, Pathologie Pathologen staf, Divisie Beeld & Oncologie, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, and van Workum, F

Published
2019

27. Urinary volatile organic compound markers and colorectal anastomotic leakage

Author

Plat, V. D., primary, Bootsma, B. T., additional, Neal, M., additional, Nielsen, K., additional, Sonneveld, D. J. A., additional, Tersteeg, J. J. C., additional, Crolla, R. M. P. H., additional, van Dam, D. A., additional, Cense, H. A., additional, Stockmann, H. B. A. C., additional, Covington, J. A., additional, de Meij, T. G. J., additional, Tuynman, J. B., additional, de Boer, N. K. H., additional, and Daams, F., additional

Published
2019
Full Text
View/download PDF

28. Structured training pathway and proctoring; multicenter results of the implementation of transanal total mesorectal excision (TaTME) in the Netherlands

Author

Veltcamp Helbach, M., primary, van Oostendorp, S. E., additional, Koedam, T. W. A., additional, Knol, J. J., additional, Stockmann, H. B. A. C., additional, Oosterling, S. J., additional, Vuylsteke, R. C. L. M., additional, de Graaf, E. J. R., additional, Doornebosch, P. G., additional, Hompes, R., additional, Bonjer, H. J., additional, Sietses, C., additional, and Tuynman, J. B., additional

Published
2019
Full Text
View/download PDF

29. Nationwide comprehensive gastro-intestinal cancer cohorts : The 3P initiative

Author

van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., van Laarhoven, H. W. M., van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and van Laarhoven, H. W. M.

Published
2018

30. Nationwide comprehensive gastro-intestinal cancer cohorts: The 3P initiative

Author

Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, MS CGO, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., van Laarhoven, H. W. M., Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, MS CGO, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and van Laarhoven, H. W. M.

Published
2018

31. Nationwide comprehensive gastro-intestinal cancer cohorts: The 3P initiative

Author

Coebergh Van Den Braak, R. R. J., Van Rijssen, L. B., Van Kleef, J. J., Vink, G. R., Berbee, M., Van Berge Henegouwen, M. I., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupé, V. M. H., Dekker, J. W. T., Van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., Van Grevenstein, W. M. U., De Groot, J. W. B., Van Grieken, N. C. T., De Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., De Noo, M. E., van de Poll-Franse, L.V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., Van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., Van Tienhoven, G., Timmermans, L. M., Tjin-a-ton, M. L. R., Van Der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., De Vos-geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., Van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., Van Laarhoven, H. W. M., Coebergh Van Den Braak, R. R. J., Van Rijssen, L. B., Van Kleef, J. J., Vink, G. R., Berbee, M., Van Berge Henegouwen, M. I., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupé, V. M. H., Dekker, J. W. T., Van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., Van Grevenstein, W. M. U., De Groot, J. W. B., Van Grieken, N. C. T., De Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., De Noo, M. E., van de Poll-Franse, L.V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., Van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., Van Tienhoven, G., Timmermans, L. M., Tjin-a-ton, M. L. R., Van Der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., De Vos-geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., Van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and Van Laarhoven, H. W. M.

Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients.Material and methods: All patients aged 18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future.Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing.Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses

Published
2018

32. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis

Author

Cardiovasculaire Epi Team 1, Heelkunde Opleiding, UMC Utrecht, Epi Methoden Team 4, Circulatory Health, JC onderzoeksprogramma Methodologie, Daniels, L., Ünlü, de Korte, N., van Dieren, S., Stockmann, H. B., Vrouenraets, B. C., Consten, E. C., van der Hoeven, J. A., Eijsbouts, Q. A., Faneyte, I. F., Bemelman, W. A., Dijkgraaf, M. G., Boermeester, M. A., Glaap, C. E M, Croonen, A., Cuesta, M. A., Kuijvenhoven, J., Buijsman, R., Den Uil, S., De Reuver, P. R., Tuynman, J. B., Van de Wall, B. J M, Stam, M. A W, Roumen, R. M H, Truin, W., Wijn, R., Gerhards, M. F., Kuhlmann, K. F D, Van der Zaag, E. S., Biemond, J. E., Klicks, R. J., Dhar, N., Cense, H. A., De Groot, G. H., Pikoulin, Y., Van Ramshorst, G. H., Hoornweg, L. L., Koet, L., Van Geloven, A. A W, Emous, M., Claassen, A. T P M, Mollink, S., Sonneveld, D. J A, Bouvé, L., Diepenhorst, G. M P, Vles, W. J., Toorenvliet, B. R., Lange, J. F., Mannaerts, G. H H, Grotenhuis, B. A., tot Nederveen Cappel, R. J De Vos, Deerenberg, E. B., Depla, A. C T M, Bruin, S., Vos, X., Scheepers, J. J G, Boom, M. J., Boerma, D., Van Esser, S., Pruim, J., Reitsma, J. B., Cardiovasculaire Epi Team 1, Heelkunde Opleiding, UMC Utrecht, Epi Methoden Team 4, Circulatory Health, JC onderzoeksprogramma Methodologie, Daniels, L., Ünlü, de Korte, N., van Dieren, S., Stockmann, H. B., Vrouenraets, B. C., Consten, E. C., van der Hoeven, J. A., Eijsbouts, Q. A., Faneyte, I. F., Bemelman, W. A., Dijkgraaf, M. G., Boermeester, M. A., Glaap, C. E M, Croonen, A., Cuesta, M. A., Kuijvenhoven, J., Buijsman, R., Den Uil, S., De Reuver, P. R., Tuynman, J. B., Van de Wall, B. J M, Stam, M. A W, Roumen, R. M H, Truin, W., Wijn, R., Gerhards, M. F., Kuhlmann, K. F D, Van der Zaag, E. S., Biemond, J. E., Klicks, R. J., Dhar, N., Cense, H. A., De Groot, G. H., Pikoulin, Y., Van Ramshorst, G. H., Hoornweg, L. L., Koet, L., Van Geloven, A. A W, Emous, M., Claassen, A. T P M, Mollink, S., Sonneveld, D. J A, Bouvé, L., Diepenhorst, G. M P, Vles, W. J., Toorenvliet, B. R., Lange, J. F., Mannaerts, G. H H, Grotenhuis, B. A., tot Nederveen Cappel, R. J De Vos, Deerenberg, E. B., Depla, A. C T M, Bruin, S., Vos, X., Scheepers, J. J G, Boom, M. J., Boerma, D., Van Esser, S., Pruim, J., and Reitsma, J. B.

Published
2017

33. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers

Author

de Cuba, E. M. V., Snaebjornsson, P., Heideman, D. A. M., van Grieken, N. C. T., Bosch, L.J.W., Fijneman, R. J. A., Belt, E., Bril, H., Stockmann, H. B. A. C., Hooijberg, E., Punt, C. J. A., Koopman, M., Nagtegaal, I. D., Coupe, V. H. M., Carvalho, B., Meijer, G. A., de Cuba, E. M. V., Snaebjornsson, P., Heideman, D. A. M., van Grieken, N. C. T., Bosch, L.J.W., Fijneman, R. J. A., Belt, E., Bril, H., Stockmann, H. B. A. C., Hooijberg, E., Punt, C. J. A., Koopman, M., Nagtegaal, I. D., Coupe, V. H. M., Carvalho, B., and Meijer, G. A.

Published
2016

34. Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion

Author

MS CGO, Circulatory Health, Cancer, Regenerative Medicine and Stem Cells, CMM Groep Snippert, CMM Groep Bos, CTI CFF, Vellinga, T T, den Uil, S, Rinkes, IHB, Marvin, D, Ponsioen, B, Alvarez-Varela, A, Fatrai, S, Scheele, C, Zwijnenburg, D A, Snippert, H, Vermeulen, L, Medema, J P, Stockmann, H B, Koster, J, Fijneman, R J A, de Rooij, J, Kranenburg, O, MS CGO, Circulatory Health, Cancer, Regenerative Medicine and Stem Cells, CMM Groep Snippert, CMM Groep Bos, CTI CFF, Vellinga, T T, den Uil, S, Rinkes, IHB, Marvin, D, Ponsioen, B, Alvarez-Varela, A, Fatrai, S, Scheele, C, Zwijnenburg, D A, Snippert, H, Vermeulen, L, Medema, J P, Stockmann, H B, Koster, J, Fijneman, R J A, de Rooij, J, and Kranenburg, O

Published
2016

35. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers

Author

MS Medische Oncologie, Cancer, de Cuba, E. M. V., Snaebjornsson, P., Heideman, D. A. M., van Grieken, N. C. T., Bosch, L.J.W., Fijneman, R. J. A., Belt, E., Bril, H., Stockmann, H. B. A. C., Hooijberg, E., Punt, C. J. A., Koopman, M., Nagtegaal, I. D., Coupe, V. H. M., Carvalho, B., Meijer, G. A., MS Medische Oncologie, Cancer, de Cuba, E. M. V., Snaebjornsson, P., Heideman, D. A. M., van Grieken, N. C. T., Bosch, L.J.W., Fijneman, R. J. A., Belt, E., Bril, H., Stockmann, H. B. A. C., Hooijberg, E., Punt, C. J. A., Koopman, M., Nagtegaal, I. D., Coupe, V. H. M., Carvalho, B., and Meijer, G. A.

Published
2016

36. Erratum: The OPTIMAP Study Group. A Simple Clinical Decision Rule to Rule Out Appendicitis in Patients with Nondiagnostic Ultrasound Results (Academic Emergency Medicine (2014) 21:5 (488-496))

Author

Leeuwenburgh, M., Stockmann, H. B., Bouma, W. H., Houdijk, A. P., Verhagen, M. F., Vrouenraets, B., Cobben, L. P., Bossuyt, P. M., Stoker, J., Boermeester, M. A., Radiology and Nuclear Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Epidemiology and Data Science, 10 Public Health & Methodologie, Amsterdam Public Health, Cancer Center Amsterdam, Surgery, and Amsterdam institute for Infection and Immunity

Published
2014

38. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial

Author

Vennix, Sandra, primary, Musters, Gijsbert D, additional, Mulder, Irene M, additional, Swank, Hilko A, additional, Consten, Esther C, additional, Belgers, Eric H, additional, van Geloven, Anna A, additional, Gerhards, Michael F, additional, Govaert, Marc J, additional, van Grevenstein, Wilhelmina M, additional, Hoofwijk, Anton G, additional, Kruyt, Philip M, additional, Nienhuijs, Simon W, additional, Boermeester, Marja A, additional, Vermeulen, Jefrey, additional, van Dieren, Susan, additional, Lange, Johan F, additional, Bemelman, Willem A, additional, Hop, W C, additional, Opmeer, B C, additional, Reitsma, J B, additional, Scholte, R A, additional, Waltmann, E W H, additional, Legemate, D A, additional, Bartelsman, J F, additional, Meijer, D W, additional, de Brouwer, M, additional, van Dalen, J, additional, Durbridge, M, additional, Geerdink, M, additional, Ilbrink, G J, additional, Mehmedovic, S, additional, Middelhoek, P, additional, Di Saverio, Salomone, additional, Boom, M J, additional, Consten, E C J, additional, van der Bilt, J D W, additional, van Olden, G D J, additional, Stam, M A W, additional, Verweij, M S, additional, Busch, O R C, additional, Buskens, C J, additional, El-Massoudi, Y, additional, Kluit, A B, additional, van Rossem, C C, additional, Schijven, M P, additional, Tanis, P J, additional, Unlu, C, additional, Gerhards, M F, additional, Karsten, T M, additional, de Nes, L C, additional, Rijna, H, additional, van Wagensveld, B A, additional, Koffeman, G I, additional, Steller, E P, additional, Tuynman, J B, additional, Bruin, S C, additional, van der Peet, D L, additional, Blanken-Peeters, C F J M, additional, Cense, H A, additional, Jutte, E, additional, Crolla, R M P H, additional, van der Schelling, G P, additional, van Zeeland, M, additional, de Graaf, E J R, additional, Groenendijk, R P R, additional, Vermaas, M, additional, Schouten, O, additional, de Vries, M R, additional, Prins, H A, additional, Lips, D J, additional, Bosker, R J I, additional, van der Hoeven, J A B, additional, Diks, J, additional, Plaisier, P W, additional, Kruyt, P M, additional, Sietses, C, additional, Stommel, M W J, additional, Nienhuijs, S W, additional, de Hingh, I H J T, additional, Luyer, M D P, additional, van Montfort, G, additional, Ponten, E H, additional, Smulders, J F, additional, van Duyn, E B, additional, Klaase, J M, additional, Swank, D J, additional, Ottow, R T, additional, Stockmann, H B A C, additional, Vermeulen, J, additional, Vuylsteke, R J C L M, additional, Belgers, H J, additional, Fransen, S, additional, von Meijenfeldt, E M, additional, Sosef, M N, additional, van Geloven, A A W, additional, Hendriks, E R, additional, ter Horst, B, additional, Leeuwenburgh, M M N, additional, van Ruler, O, additional, Vogten, J M, additional, Vriens, E J C, additional, Westerterp, M, additional, Eijsbouts, Q A J, additional, Bentohami, A, additional, Bijlsma, T S, additional, de Korte, N, additional, Nio, D, additional, Govaert, M J P M, additional, Joosten, J J A, additional, Tollenaar, R A E M, additional, Stassen, L P S, additional, Wiezer, M J, additional, Hazebroek, E J, additional, Smits, A B, additional, van Westreenen, H L, additional, Lange, J F, additional, Brandt, A, additional, Nijboer, W N, additional, Toorenvliet, B R, additional, Weidema, W F, additional, Coene, P P L O, additional, Mannaerts, G H H, additional, den Hartog, D, additional, de Vos, R J, additional, Zengerink, J F, additional, Hoofwijk, A G M, additional, Hulsewé, K W E, additional, Melenhorst, J, additional, Stoot, J H M B, additional, Steup, W H, additional, Huijstee, P J, additional, Merkus, J W S, additional, Wever, J J, additional, Maring, J K, additional, Heisterkamp, J, additional, van Grevenstein, W M U, additional, Vriens, M R, additional, Besselink, M G H, additional, Borel Rinkes, I H M, additional, Witkamp, A J, additional, Slooter, G D, additional, Konsten, J L M, additional, Engel, A F, additional, Pierik, E G J M, additional, Frakking, T G, additional, van Geldere, D, additional, Patijn, G A, additional, D'Hoore, A J L, additional, de Buck van Overstraeten, A, additional, Miserez, M, additional, Terrasson, I, additional, Wolthuis, A, additional, and De Blasiis, M G, additional

Published
2015
Full Text
View/download PDF

40. Accuracy of MRI compared with ultrasound imaging and selective use of CT to discriminate simple from perforated appendicitis

Author

Leeuwenburgh, M M N, primary, Wiezer, M J, additional, Wiarda, B M, additional, Bouma, W H, additional, Phoa, S S K S, additional, Stockmann, H B A C, additional, Jensch, S, additional, Bossuyt, P M M, additional, Boermeester, M A, additional, Stoker, J, additional, Gratama, J W C, additional, Houdijk, A P J, additional, Richir, M, additional, Spilt, A, additional, van Es, H W, additional, Verhagen, M F, additional, Vrouenraets, B C, additional, and Cobben, L P J, additional

Published
2013
Full Text
View/download PDF

41. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer

Author

Snoeren, N, primary, Emmink, B L, additional, Koerkamp, M J G, additional, van Hooff, S R, additional, Goos, J A C M, additional, van Houdt, W J, additional, de Wit, M, additional, Prins, A M, additional, Piersma, S R, additional, Pham, T V, additional, Belt, E J, additional, Bril, H, additional, Stockmann, H B, additional, Meijer, G A, additional, van Hillegersberg, R, additional, Holstege, F C, additional, Jimenez, C R, additional, Fijneman, R J A, additional, Kranenburg, O W, additional, and Rinkes, I H M Borel, additional

Published
2013
Full Text
View/download PDF

43. Normal dystrophin in McLeod myopathy

Author

Danek, Adrian, primary, Witt, Thomas N., additional, Stockmann, H. B. A. C., additional, Weiss, Barbara J., additional, Schotland, Donald L., additional, and Fishbeck, Kenneth H., additional

Published
1990
Full Text
View/download PDF

44. Erratum: Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study.

Author

Seesing, M F J, Veen, A van der, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, Wildenberg, F J H van den, Henegouwen, M I van Berge, Duijvendijk, P van, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, Hillegersberg, R van, and Group, Gastroesophageal Metastasectomy

Subjects
LIVER metastasis, ESOPHAGEAL cancer, STOMACH cancer, METASTASIS, SURGICAL excision, LUNG cancer
Published
2019
Full Text
View/download PDF

46. Treatment, follow-up and microbiota in acute diverticulitis

Author

Daniels, L., Boermeester, Marie A., Stockmann, H. B. A. C., Dijkgraaf, Marcel G. W., Other departments, Boermeester, M.A., Stockmann, H.B.A.C., Dijkgraaf, M.G.W., and Faculteit der Geneeskunde

Abstract

Er bestaat veel controverse rondom diverticulitis. Er is tegenstrijdigheid omtrent de beste behandeling van de verschillende stadia. Voor acute ongecompliceerde diverticulitis is het onzeker of antibiotica nodig zijn. De waarde van routine follow-up colonoscopie wordt betwijfeld. Er bestaat onduidelijkheid over de aanpak van recidiverende diverticulitis. Ten slotte is de pathogenese niet geheel bekend. Aan de basis van dit proefschrift staat de DIABOLO trial, een gerandomiseerde multicentrische klinische trial die het effect van antibiotica op het ziektebeloop van acute ongecompliceerde diverticulitis onderzoekt. Tevens werden twee vergelijkende cohort studies en (systematische) reviews uitgevoerd en een hypothese ontwikkeld. De DIABOLO trial toont aan dat antibiotica veilig weggelaten gelaten kunnen worden bij de behandeling van primaire acute ongecompliceerde diverticulitis. Routine follow-up colonoscopie na CT-bewezen ongecompliceerde diverticulitis kan achterwege gelaten worden. Er is weinig bewijs voor medicamenteuze therapieën ter preventie van recidiverende diverticulitis. Diverticulitis patiënten hebben een hogere diversiteit van fecale microbiota dan controles. Middels microbioom analyse kan de diagnose diverticulitis met relatief goede accuratesse gesteld worden. Een veranderde microbiota samenstelling is een plausibele factor in de pathogenese, die waarschijnlijk multifactorieel is en het resultaat van complexe interacties. Bleven internationale richtlijnen eerder ongewijzigd, omdat gesteld werd dat meer onderzoek nodig is alvorens een antibiotica-vrije behandelstrategie in te voeren, nu is er voldoende bewijs voor de implementatie van een observationele behandelstrategie. Hetzelfde geldt voor het achterwege laten van routine follow-up colonoscopie na een CT-bewezen ongecompliceerde episode. Ten aanzien van de darm microbiota zijn verdere studies noodzakelijk. Dit zou kunnen leiden tot diagnostische, preventieve en therapeutische toepassingen.

Published
2015

47. Cost-effectiveness of selective decontamination of the digestive tract to decrease infectious complications in colorectal cancer surgery: An analysis of the SELECT trial.

Author

Reuvers JRD, Gaikhorst E, Ben ÂJ, Scholten J, van Egmond M, Bosmans JE, Stockmann HBAC, Kazemier G, Tuynman JB, Abis GSA, and Oosterling SJ

Subjects
Humans, Cost-Benefit Analysis, Decontamination, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Anti-Bacterial Agents therapeutic use, Colorectal Neoplasms surgery, Colorectal Neoplasms drug therapy
Abstract

Introduction: Selective decontamination of the digestive tract (SDD) is effective in reducing infectious complications in elective colorectal cancer (CRC) surgery. However, it is unclear whether SDD is cost-effective compared to standard antibiotic prophylaxis., Material & Methods: Economic evaluation alongside multicenter randomized controlled trial, the SELECT-trial, from a healthcare perspective. Patients included underwent elective surgery for non-metastatic CRC. The intervention group received oral non-absorbable colistin, tobramycin and amphotericin B (SDD) next to standard antibiotic prophylaxis. Both groups received a single shot intravenous cefazolin and metronidazole preoperatively as standard prophylaxis. Occurrence of postoperative infectious complication in the first 30 postoperative days was extracted from medical records, Quality-Adjusted Life-Years (QALYs) based on the ED-5D-3L, and healthcare costs collected from the hospital's financial administration., Results: Of the 455 patients, 228 were randomly assigned to intervention group and 227 patients to the control group. SDD significantly reduced the number of infectious complications compared to control (difference = -0.13, 95 % CI -0.05 to -0.20). No difference was found for QALYs (difference = 0.002, 95 % CI -0.002 to 0.005). Healthcare costs were statistically significantly lower in the intervention group (difference = -€1258, 95 % CI -2751 to -166). The ICER was -9872 €/infectious complication prevented and -820,380 €/QALY gained. For all willingness-to-pay thresholds, the probability that prophylactic SDD was cost-effective compared to standard prophylactic practice alone was 1.0., Conclusion: The addition of SDD to the standard preoperative intravenous antibiotic prophylaxis is cost-effective compared to standard prophylactic practice from a healthcare perspective and should be considered as the standard of care., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 Published by Elsevier Ltd.)

Published
2023
Full Text
View/download PDF

48. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Author

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, and van Laarhoven HWM

Subjects
Biological Specimen Banks, Cohort Studies, Humans, Registries, Gastrointestinal Neoplasms, Observational Studies as Topic methods, Randomized Controlled Trials as Topic methods, Research Design
Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients., Material and Methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future., Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing., Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting.

Published
2018
Full Text
View/download PDF

49. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

Author

de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, and Meijer GA

Subjects
Adult, Aged, Aged, 80 and over, Colonic Neoplasms mortality, Colonic Neoplasms pathology, Female, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Colonic Neoplasms genetics, Microsatellite Instability, Mutation, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics
Abstract

Microsatellite instability (MSI) has been associated with favourable survival in early stage colorectal cancer (CRC) compared to microsatellite stable (MSS) CRC. The BRAF V600E mutation has been associated with worse survival in MSS CRC. This mutation occurs in 40% of MSI CRC and it is unclear whether it confers worse survival in this setting. The prognostic value of KRAS mutations in both MSS and MSI CRC remains unclear. We examined the effect of BRAF and KRAS mutations on survival in stage II and III MSI colon cancer patients. BRAF exon 15 and KRAS exon 2-3 mutation status was assessed in 143 stage II (n = 85) and III (n = 58) MSI colon cancers by high resolution melting analysis and sequencing. The relation between mutation status and cancer-specific (CSS) and overall survival (OS) was analyzed using Kaplan-Meier and Cox regression analysis. BRAF V600E mutations were observed in 51% (n = 73) and KRAS mutations in 16% of cases (n = 23). Patients with double wild-type cancers (dWT; i.e., BRAF and KRAS wild-type) had a highly favourable survival with 5-year CSS of 93% (95% CI 84-100%), while patients with cancers harbouring mutations in either BRAF or KRAS, had 5-year CSS of 76% (95% CI 67-85%). In the subgroup of stage II patients with dWT cancers no cancer-specific deaths were observed. On multivariate analysis, mutation in either BRAF or KRAS vs. dWT remained significantly prognostic. Mutations in BRAF as well as KRAS should be analyzed when considering these genes as prognostic markers in MSI colon cancers., (© 2015 UICC.)

Published
2016
Full Text
View/download PDF

50. Overtreatment of sigmoid diverticulitis: plea for a less aggressive approach.

Author

Daniels L, de Korte N, Winter D, Boermeester MA, and Stockmann HB

Subjects
Diverticulitis, Colonic classification, Diverticulitis, Colonic complications, Diverticulitis, Colonic prevention & control, Elective Surgical Procedures, Humans, Colon, Sigmoid pathology, Diverticulitis, Colonic therapy
Abstract

A less invasive approach to the treatment of left-sided colonic diverticulitis has emerged in the last decade. The standard of care for perforated or complicated diverticulitis evolved from a Hartmann's procedure, to resection and primary anastomosis, to treatment with antibiotics and percutaneous drainage in a carefully selected (Hinchey grade 2) patient subset. Recently, laparoscopic lavage emerged as a promising less invasive treatment for selected cases of Hinchey 3 patients. Likewise, for nonperforated or uncomplicated diverticulitis the approach is becoming less aggressive with a change from intravenous antimicrobial therapy, starvation and admission, to oral antibiotics and finally to observation and outpatient treatment. This less invasive or aggressive approach is due to expanding evidence on optimal treatment and is congruent with an increasing understanding that diverticulitis comprises different disease entities with heterogeneity between patients. The disease should be targeted by specific approaches, after a meticulous assessment of the diverticulitis stage, and tailored to an individual basis. Avoidance of overtreatment has obvious benefits: less in-hospital treatment, cost reduction, diminished development of antimicrobial resistance, reduction in complication rate and side effects and presumably a better quality of life for the patient. In conclusion, one might say we have overtreated the majority of diverticulitis patients for decades. More research is needed to explain the pathogenesis and multifactorial etiology and in the near future hopefully several unanswered questions regarding the optimal management of patients with different stages of diverticulitis will be answered by various ongoing trials., (Copyright © 2012 S. Karger AG, Basel.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results